HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $100
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $110 to $100.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $110 to $100.